Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Change in Taxes (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Change in Taxes for 12 consecutive years, with $472000.0 as the latest value for Q4 2025.

  • Quarterly Change in Taxes fell 96.33% to $472000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$15.5 million through Dec 2025, down 997.6% year-over-year, with the annual reading at -$15.5 million for FY2025, 997.6% down from the prior year.
  • Change in Taxes hit $472000.0 in Q4 2025 for Ani Pharmaceuticals, up from -$12.5 million in the prior quarter.
  • In the past five years, Change in Taxes ranged from a high of $12.9 million in Q4 2024 to a low of -$14.3 million in Q2 2024.
  • Historically, Change in Taxes has averaged -$634400.0 across 5 years, with a median of -$148000.0 in 2021.
  • Biggest five-year swings in Change in Taxes: skyrocketed 15538.78% in 2023 and later crashed 3942.21% in 2024.
  • Year by year, Change in Taxes stood at -$637000.0 in 2021, then soared by 92.31% to -$49000.0 in 2022, then surged by 15538.78% to $7.6 million in 2023, then soared by 69.9% to $12.9 million in 2024, then tumbled by 96.33% to $472000.0 in 2025.
  • Business Quant data shows Change in Taxes for ANIP at $472000.0 in Q4 2025, -$12.5 million in Q3 2025, and -$10.9 million in Q2 2025.